Adenovirus (adv) is a significant cause of morbidity and mortality in pediatric hematopoietic stem cell transplant recipients, and control of infection seems to require antigen-specific T cells. We evaluated the recovery of adv-specific cellular immunity in this patient population related to degree of T-cell immunosuppressive therapy and compared this to adv cellular immunity of normal donors. Over 12 months, we monitored for adv DNA in stool and blood of patients and in the blood of a normal donor group. Twenty-two pediatric hematopoietic stem cell transplant (HSCT) patients (14 months-20 years) who received matched-related (MRD n ¼ 6), mismatched related (Haplo n ¼ 6) or matched unrelated donor (MUD n ¼ 10) grafts, were followed and results compared to healthy controls (n ¼ 8). Adv was detected by polymerase chain reaction in blood and/or stool from 81.8% of patients on at least one occasion post-HSCT, but only 68% of patients developed symptomatic adv infections. Recovery of adv-specific T cells was significantly delayed in the MUD and Haplo recipients, whereas recovery in the MRD group was similar to levels detected in healthy donors within 30 days post-transplant. In conclusion, recipients of alternative donor transplants at our institution have significantly delayed adv-specific cellular immune recovery, which correlates to an increased risk of adv-associated morbidity and mortality.
Introduction
Humans are susceptible to infection with 51 serotypes of Adenovirus (adv), forming six distinct groups (A-F), 1 and while infections are effectively controlled in healthy individuals, adv has emerged as a significant cause of morbidity and mortality in immunocompromised individuals. Retrospective studies of hematopoietic stem cell transplant (HSCT) patients have indicated that a spectrum of serotypes, including 2, 5, 7, 9, 11, 34 and 35, can be responsible for disease. 2, 3 In the HSCT population infection is usually detected in the first 30 days post-transplant, and infection rates vary from o5 to 50%. [2] [3] [4] [5] [6] [7] [8] [9] This broad range is likely due to differential sensitivity of detection methods and the frequency with which the screening was carried out. 2, 7, 10 Nevertheless, with the advent of highly sensitive polymerase chain reaction (Q-PCR)-based assays, it is becoming increasingly difficult for physicians to assess the clinical relevance of such positive results. 7 A number of factors have been reported to be associated with risk of adv infection post-transplant including the lack of recovery of antigen-specific T cells. Initial studies by Chakrabarti et al. 11 showed an association between post transplantation lymphocyte recovery and adv infection. This observation was extended by Feuchtinger et al., 12, 13 who demonstrated that the recovery of adv antigen-specific T cells was crucial for the clearance of infection. In addition, Runde et al. 9 suggested that adv antibodies in the donor, indicating a recent exposure to adv, could also be a risk factor in the development of infection. Taking these studies into account, we sought to prospectively monitor the recovery of adv-specific T cells in pediatric HSCT recipients at Texas Children's Hospital while concurrently monitoring adv load in stool and blood. To better define the clinical relevance of adv detection using Q-PCR and the normal cellular immune response to adv, we also serially monitored healthy controls at risk of frequent exposure to adv.
We divided the patients into three groups; matchedrelated donor (MRD), matched unrelated donor (MUD) and Haplo-identical (Haplo) stem cell transplant (SCT) recipients. In patients where we detected evidence of infection we identified the infecting species using speciesspecific primer-probe combinations. Concurrently, we evaluated adv-specific T-cell recovery in the patient populations and compared the number of adv-responsive T cells in these patients to that of a healthy control group.
We found that the frequency of viremia in our patient population, as defined by a Q-PCR result of 41500 adv cp/ ml blood, was 36% (8/22) , with 88% (7/8) of this population displaying symptoms at the time of detection. This level was established based on detection of adv in blood samples from the healthy controls who had measurable adenoviral loads (o1500 cp/ml) but remained asymptomatic for adv. Time to viremia was substantially earlier in the MUD and Haplo groups than in recipients of MRD stem cell products (o112 days in the MUD and Haplo groups versus 4300 days in the MRD group). Detection of adv in stool and adv-associated enteritis occurred in 13 of the 14 patients who submitted a stool sample. First detection in the stool of these patients occurred before day þ 68 in 12/14 (86%).
Our analysis indicates that recovery of antigen-specific T cells seems to be crucial for protection against the development of infection as a number of the analyzed patients demonstrated specific T-cell expansion after secondary exposure to adv in a manner similar to changes in adv-specific T-cell number in healthy controls experiencing asymptomatic adv viremia. This study will allow physicians to better interpret the clinical relevance of positive Q-PCR results and to identify patients who would benefit from therapeutic intervention.
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Methods
Study subjects
The protocol was approved by the Institutional Review Board (Baylor College of Medicine). We obtained informed consent from 22 patients to assess the frequency of adv positivity in their blood7stool by Q-PCR and assess advspecific cellular immune recovery over a 12-month period. The patients analyzed were divided into three groups; MRD, MUD and Haplo SCT recipients ( All products were CD34 þ selected peripheral blood stem cells. One patient received mini-methotrexate/FK506 GvHD prophylaxis as their graft contained 45 Â 10 4 CD3 þ cells/kg.
MRD. All six patients received Cytarabine 3 g/m 2 Â 6, Cyclophosphamide 45 mg/kg Â 2, 1200 cGY TBI and cyclosporine/mini-methotrexate as GvHD prophylaxis. 18 No patients received alemtuzumab. All patients received marrow-derived products.
Supportive care
The patients were all cared for in private rooms with highefficiency particulate air filter. All patients received antibacterial, anti-cytomegalovirus (CMV), anti-herpes simplex virus (HSV), and anti-fungal prophylaxis as dictated by institutional protocols. Intravenous immunoglobulin (IVIG) was given as infection prophylaxis at 500 mg/kg monthly through day þ 100. CMV prophylaxis with ganciclovir or foscarnet was given to all patients who were CMV seropositive or who received grafts from seropositive donors. Prophylaxis was given at 5 mg/kg i.v. b.i.d. for 14 days and then daily, Monday-Friday until day þ 100. The prophylaxis was given to 33% (2/6) of MRD, 50% (5/10) MUD and 83% (5/6) Haplo recipients owing to the positive serologic status of the donor or the patient. CMV PCR or antigenemia were screened at weekly intervals on all patients. Screening of patient samples for other infectious agents including adv was performed as clinically deemed necessary by treating physicians. Specifically, respiratory and/or gastroenterological and/or urinary tract symptoms would prompt culture with or without Q-PCR in addition to any study assays performed. The decision to treat with cidofovir was left to the treating physician and only one patient (MUD) received cidofovir.
DNA extraction. DNA was extracted from blood and stool samples using Qiagen blood mini-kits and stool minikits per the manufacturer's instructions (Qiagen, Hilden, Germany).
Blood and stool sampling Healthy controls. Peripheral blood (30 ml) was drawn monthly over a 12-month period. Peripheral blood mononuclear cells (PBMCs) were isolated via Ficoll method and frozen in liquid nitrogen for later evaluation of adv-specific T-cell number by enzyme-linked immunosorbent spot assay (ELISPOT). Blood (1 ml) was used for DNA extraction for adv/Q-PCR evaluation.
Patients. PBMCs from 1 ml/kg up to 30 ml of peripheral blood were extracted monthly over a 12-month period, and were isolated as previously described and cryopreserved. Blood (2 ml) was drawn weekly for the first 6 weeks after transplant for adv/Q-PCR. Stool for Q-PCR was collected weekly during the first 6 weeks after transplant, and if symptoms of diarrhea developed. Not all patients gave stool samples routinely as requested, however all patients with gastroenteritis symptoms provided samples.
PCR. The presence of adenoviral DNA from all 51 species of adv was evaluated by Q-PCR assay as previously published by Heim et al. 19 Species analysis of positive samples by Q-PCR was performed as previously published by Lion et al. 20 All real-time, quantitative Q-PCR reactions were carried out on the Applied Biosystems (ABI) (Foster City, CA, USA) PRISM 7700 Sequence Detector and analyzed with ABI Sequence Detection System software ver. 1.9.1.
Flow cytometry
For all flow cytometric analyses, a FACSCalibur instrument (Becton Dickinson (BD), Mountain View, CA, USA) was used to acquire, and CellQuest software (BD) to analyze, data. Antibodies against CD3, 4 and 8 were purchased from BD. Isotype controls for all antibody staining were immunoglobulin G1-phycoerythrin (IgG1-PE), IgG1-peridinin chlorophyll protein (IgG1-PerCP) and IgG1-fluorescein isothiocyanate (IgG1-FITC). Phosphatebuffered saline (PBS) (Sigma, St Louis, MO, USA) with 2% fetal bovine serum and 0.1% sodium azide (Sigma) was used as wash buffer. PBS with 0.5% paraformaldehyde (Sigma) was used as fixative solution. Cells were washed once with wash buffer, pelleted, and antibodies were added to the pellet in saturating amounts (5 ml). After 15-min incubation at 41C in the dark, cells were washed twice, fixed and analyzed.
ELISPOT
The ELISPOT assay, as described previously, 21 was used to determine the precursor frequency of adv-specific interferon-g (IFN-g)-secreting T cells. Briefly, PBMC were isolated by Ficoll (Lymphoprep, Nycomed, Oslo, Norway) gradient separation. In order to eliminate inter-ELISPOT plate variability as a source of error in evaluating adv-specific T cells in PBMC, all samples were frozen until the end of the follow-up period. Following thaw, 2-5 Â 10 6 PBMC were incubated with adv 5/f35 vector 21 for 2 h at a multiplicity of infection of 200, then washed in PBS and plated in ELISPOT trays at 4 Â 10 5 PBMC/well in triplicate. Monocytes in the mixed PBMC population become transduced by adv 5/f35 vector and present adenoviral antigens to T cells. Unstimulated PBMC at 2 Â 10 5 served as negative controls, and PBMC's stimulated with CMV pp65 peptide library and staphylococcal antigen were used as positive controls. After 20 h of incubation, plates were developed as described previously. 21 After overnight drying at room temperature in the dark, plates were sent for evaluation to Zellnet Consulting, New York, NY, USA.
Statistical methods
Time to viremia was determined for each patient using the Kaplan-Meier curve. Median times to viremia were estimated from the Kaplan-Meier curve and a comparison across the three transplant groups was performed using the log-rank test. As an alternative approach, the incidence of adv viremia was estimated using the cumulative incidence estimator in order to take into account for competing risks of relapse and death. [22] [23] [24] The competing risk approach yielded essentially identical results to the Kaplan-Meier method (data not shown).
Descriptive statistics were calculated to summarize adenoviral load, immune recovery parameters, and advspecific T cells by transplant group at each time point of follow-up. Changes in these outcomes from baseline measurements were calculated and compared using the Wilcoxon signed-ranks test. Pairwise comparisons of the outcomes in each of the MUD and Haplo groups versus the MRD group were performed using the two-sample t-test or the Wilcoxon rank-sum test. A comparison of each of the transplant groups with the healthy control samples was also performed. The kinetics of adv T-cell recovery was evaluated by calculating area under the curve (AUC) using the trapezoidal method. Pairwise comparisons of AUCs were likewise performed using two-group comparison methods.
Results
Twenty-two children who received allogeneic transplants at Texas Children's Hospital in 2003 were followed for 12 months in order to detect adv and measure the recovery of adv-specific cellular immunity post-transplant. We examined serial blood7stool samples by Q-PCR to measure viral load. Antigen-specific T-cell recovery was evaluated at the same time points. Our control group was a cohort of eight healthy controls in whom we analyzed rates of adv detection in peripheral blood by Q-PCR and levels of advspecific T cells using ELISPOT assays over a 12-month period.
GvHD prophylaxis
As withdrawal of lymphocyte immune suppression has been shown to be the primary treatment modality for adv infection, we recorded the time to withdrawal of immune suppression in these patients. The mean time for the use of systemic GvHD prophylaxis was not significantly different in MUD and MRD recipients at 213 and 169 days, respectively (P ¼ 0.5). Haplo recipients did not receive systemic immune suppression after BMT unless CD3 þ cells/kg infused with the product were 45 Â 10 5 (n ¼ 1) (Table 1) . Only one MUD recipient developed 4grade II GvHD, which involved gut and skin (Table 1) .
Detection of adv (entire population)
In all, 15/22 (68%) patients had adv detected by Q-PCR in the peripheral blood on at least one occasion (Table 1) . Eight of 22 pediatric transplant recipients (36%) had levels 41500 cp/ml adv DNA in the blood. Seven of the eight patients (88%) with levels of 41500 cp/ml had a symptomatic infection (diarrhea7fever). However, eight other patients were symptomatic with adv-associated gastroenteritis (as determined by Q-PCR and/or culture) despite having low levels (o1500 cp/ml) of adv in the blood. Overall, 13/15 (87%) patients, who provided stool for analysis, had adv detected by Q-PCR in stool on at least one occasion. In all of these patients the positivity in the stool was associated with symptoms (diarrhea, abdominal pain, anorexia7fever). All of these 13 patients were able to clear the virus without sequelae.
One Haplo patient (who had a maximum adv Q-PCR in the blood of 56 000 cp/ml) had symptomatic adv infection (respiratory failure, hepatic dysfunction and enteritis), and succumbed to infection 90 days post-transplant. Adv was cultured from multiple organs at autopsy. The remaining seven viremic patients were able to clear the adv including one MUD transplant recipient who was treated with cidofovir and weaning of immune suppression.
Detection of adv in population subgroups (MRD, MUD, Haplo)
We subdivided our patients into recipients of grafts from MRD, MUD or Haplo donors, in order to analyze whether there were any differences between the three groups in terms of; (a) detection of adv in stool and blood, and (b) time to viremia (defined as PCR levels 41500 adv cp/ml blood) post-transplant. In all, 22.7% (5/22) of patients had adv at any level detected in their blood only, 13.6% (3/22) were Q-PCR positive in their stool only, and 45.4% (10/22) were positive in the blood and stool. Although we could not determine true infection rates (as we did not screen nasal secretions, throat swabs or urine) we determined that (a) adv detection (at any level) from stool and/or blood was similar in all three groups (66.6% MRD, 90% MUD and 83.3%, Haplo), and (b) the rate of viremia was also similar (16.6% MRD, 50% MUD, and 33% Haplo; P ¼ 1) ( Table 1 ). The Kaplan-Meier curve for detection of 41500 cp/ml adv in blood shows that patients who received grafts from MUD and Haplo donors had similar frequencies of viremia, which were detected early (Figure 1) , however small patient numbers in each group limited our ability to detect statistically significant differences in these rates. Although adv-associated viremia occurred significantly earlier in the MUD patients (days 27-99) and Haplo recipients (days 34-112), only one MRD patient developed evidence of adv-associated viremia which was detected at day 4300 post-transplant while the patient remained asymptomatic (Figure 1) .
Although detection of 41500 cp/ml adv defined viremia, this did not always coincide with the presence of advassociated symptoms. In contrast, detection in the stool was generally early in the course and always corresponded with symptoms of enteritis. Symptomatic viremia rates were substantially higher in the MUD (50%) and Haplo (33%) patients in comparison with the MRD recipients (0%). Clinical symptoms such as diarrhea or prolonged fever with multiple adv Q-PCR-positive blood and stool assays were observed in 5/5 MUD and 2/2 Haplo recipients with 41500 adv cp/ml in blood. In contrast, there were no clinical symptoms associated with detection of adv in the blood of MRD recipients and only 1/6 MRD patients had viremia as defined by 41500 cp/ml.
Detection of adv by Q-PCR in the stool always preceded detection in blood. The three MRD recipients who had adv detected in their stool had symptoms of diarrhea and fever within the first 60 days post-transplant. Despite the symptomatic enteritis, only one of these three patients had adv detected in the blood, which did not occur during the enteritis but was detected at 1500 cp/ml 9 months posttransplant with no notable symptoms. All seven MUD recipients who were Q-PCR positive for adv in their stool had symptoms of diarrhea in the first 30 days posttransplant, and four of these patients developed viremia. All three Haplo recipients who were Q-PCR positive for adv in their stool were symptomatic and became Q-PCR positive for adv in the blood, with only one developing viremia (>1500 cp/ml).
Adv Q-PCR of donor stem cell product As the symptomatic infections were predominantly in the early post-transplant period (p30 days), we extracted DNA from the pre-processed donor marrow/PBMC samples in all 22 patients and analyzed these samples for the presence of adv as a potential source of infection. However, we were unable to detect any evidence of infection, therefore it is unlikely that the donor graft was the virus source (data not shown).
Adv species-specific Q-PCR Using subgroup-specific Q-PCR analysis we identified the species of the infecting viruses. Species C was detected in 14/15 patients with a Q-PCR-positive blood sample (at any level), one patient was coinfected with species F/G and the remaining patient was infected with a species A virus in their blood (Table 2 ). Thirteen patients were positive for adv in the stool. Five of these were infected with just one species, whereas the remaining eight patients had evidence of two or more adv species by Q-PCR analysis. Species A and C were detected most frequently (9/13 and 10/13, respectively), followed by F/G (7/13), B (2/13), and D 
Table 2
Adv species data: adv from species C predominated in blood in all groups
Abbreviations: Haplo ¼ haploidentical donor; MRD ¼ matched related donor; MUD ¼ matched unrelated donor; Pt ¼ patient; PB ¼ peripheral blood. Multiple species of adv were detectable in stool samples.
(1/13) and E (1/13) ( Table 2 ). There was no correlation between infection with multiple species and severity of symptoms. Not all species were detected on each positive sample from a patient.
General cellular immune recovery
Delayed recovery of T-cell immunity has been suggested to be a factor in the development of adv infections posttransplant. Therefore, we measured the absolute lymphocyte count (ALC) and recovery of antigen-specific T cells in the MRD, MUD and Haplo recipients. The ALC, CD4 þ T-cell counts or the CD8 þ T cell counts were not significantly different between the three groups over the 12-month follow-up period (data not shown), and all three groups had ALC 41000 by 6 months. In fact, the mean ALCs for the MRD and MUD patients were almost 1000 by 3 months post-transplant. We compared ALC recovery and CD8 þ T-cell recovery in patients with and without adv infection, regardless of donor status, and found no difference in lymphocyte recovery (data not shown).
Adv-specific cellular immune recovery in patients
When we evaluated the recovery of adv-specific T cells in the same groups of patients and compared the frequency of antigen-specific cells with those detected in our healthy control group, we found that at 3 months the MRD recipients had similar numbers of circulating adv-specific T cells to healthy controls (Figure 2 ). In fact, by 1 month post-transplant there was no statistically significant difference in adv-specific T-cell numbers between MRD recipients and healthy controls (Figure 2 ). In contrast, the MUD and Haplo recipients had significantly fewer circulating adv-specific T cells at 3 months point (Figure 2 ). When the same comparison was carried out at 6 months posttransplant adv-specific T cells had recovered to normal levels in the MUD group; however the Haplo recipients had a significantly delayed recovery of specific T cells, which did not reach normal levels until 12 months post-transplant ( Figure 2) . In an effort to better understand the kinetics of virusspecific immune recovery, we evaluated the rate at which adv-specific T cells recovered in our patients. When comparing the rate of recovery of antigen-specific T cells between the MRD, MUD and Haplos, we found that only the MRDs had rapid recovery of adv-specific T cells, which were detectable even at 1 month post-transplant. However, by 3 months post-transplant the MUD recipients had some evidence of virus-specific cellular immunity at levels similar to the MRD recipients (P ¼ 0.036 at 1 month, and 0.11 at 3 months). By 6 months post-transplant, all groups showed evidence of adv-specific T-cell recovery (Figure 2) , however, the rate of recovery was significantly faster in the MRD recipients in comparison to the MUD (P ¼ 0.05) and Haplo (P ¼ 0.03) recipients (Figure 3) .
Of the eight patients with viremia, only the asymptomatic patient (MRD recipient) had detectable levels of advspecific T cells in their blood at the time of viremia. However, in the majority of patients who had evidence of a rising viral load we could eventually detect a subsequent increase in adv-specific T cells in the peripheral blood. For example, Figure 4a and b show the course of adv infection and viral clearance in two representative MUD transplant recipients. In Figure 4a , adv was detectable in both blood and stool samples pre-transplant. After 1 month posttransplant, the patient developed fever and diarrhea and the levels in blood and stool peaked at 10 000 cp/ml blood and 41 Â 10 7 cp/g stool. However, adv was completely cleared from both sites by 5 months post-transplant. This resolution of infection corresponded with a concurrent increase in adv-specific T cells, which increased from 0 to 190 SFC/10 6 PBMCs by 2 months post-transplant. This was the only MUD patient to have detectable adv-specific T cells before the 3-month time point. Further, the antigenspecific cells remained detectable out to 14 months posttransplant. Figure 4b shows trends in peripheral blood adv DNA levels and adv-specific T-cell recovery in another MUD recipient, who was treated with high dose steroids, antitumor necrosis factor-a and anti-CD25 therapy for GvHD early post-transplant. By day þ 60 she was febrile and blood samples showed a rising adenoviral load from 350 cp/ml on day þ 62 to 46 000 cp/ml on day þ 103 when immune suppression was weaned. After a 30 day course of cidofovir, the adv load was 18 000 cp/ml and approximately 20 and 40 days later levels had decreased to 1300 and 0 cp/ ml, respectively. She had one subsequent positive Q-PCR level of 41500 adv cp/ml (day 208) but this was not associated with symptoms. When we examined the patient's immune response to adv, we were able to detect a large expansion of adv-specific T cells by day þ 150 (5 months), which corresponded to viral clearance. Throughout the remainder of the monitoring period, she showed the ability to respond to adv stimulus and remained symptom free as shown by a two-to fourfold expansion of adv-specific T cells in response to the asymptomatic viremia at 7 months (day 208) post-transplant.
Adv cellular immunity in healthy controls
We measured the frequency of adv-specific T cells as well as viral load in the peripheral blood of eight healthy controls. None of the controls displayed symptoms suggestive of adv infection (conjunctivitis, upper respiratory tract infection and enteritis) during the monitoring period. The mean number of antigen-specific T cells over a 12-month period ranged from 21 to 328 adv SFU/10 6 PBMC in the eight individuals.
We detected adv in the peripheral blood of three controls. Figure 5 shows the trend in adv-specific T lymphocytes of one of the healthy control who had adv DNA detected at three different time points. In all three healthy controls who were Q-PCR positive for adv in the blood at some point in the monitoring, the subsequent increase in adv-specific T cells was two-to-threefold ( Figure 5 ), which returned to baseline when the Q-PCR became negative. We did not evaluate any other body fluid for the presence of adv, therefore fluctuations in advspecific T-cell numbers may be related to exposure in the nasopharyngeal or gastrointestinal tracts of individuals who were not found to be positive in blood. 
Discussion
We performed a prospective study in pediatric allogeneic HSCT patients to determine the frequency of adv positivity by Q-PCR, to evaluate the length of time to adv-specific Tcell recovery, and to ascertain whether the donor graft is a primary source for adv. In addition, we analyzed a healthy control population at high risk of exposure to adv as a control group. We defined adv infection as detection of adv at any level at any site, viremia as detection of adv in the blood at levels 41500 cp/ml, and disease as detection of adv Xtwo sites which was associated with symptoms. As the recovery of adv-specific T cells has been suggested to be protective against the development of infection, and immune suppression has been shown to delay the recovery of T cells, 12 we subdivided the patient populations into three groups; (i) recipients of MRD HSCTs who received no T-cell depletion, (ii) recipients of MUD transplants who received in vivo T-cell depletion with alemtuzumab, and (iii) Haplo transplant recipients who received CD34-selected grafts and in vivo T-cell depletion with alemtuzumab. Although small patient numbers limited the study, the differences in the extent of T-cell depletion and the longitudinal nature of the study provided significant and detailed immunity assessments for the pediatric patient population.
We found that adv viremia was not significantly different in the three groups (16.6% MRD, 50% MUD and 33%, Haplo). However, viremia occurred earlier in the posttransplant period in MUD and Haplo recipients (o112 days) than in the MRD recipients (4300 days). The confirmed source of this infection was not the donor stem cell product as Q-PCR analysis was uniformly negative, suggesting that patients may have been previously exposed or become infected after transplant from environmental/ contact sources. In fact, as eight patients had one or more species of adv identified in the stool at admission or within 30 days after HSCT, it appears that patients may harbor multiple species of adv in an asymptomatic state as they enter the transplant unit.
Sixty-eight percent (15/22) of patients were positive by Q-PCR in the blood (at any level) and 59% (13/22) of all patients and 87% (13/15) of those who gave stool samples were positive in the stool on at least one occasion over the 12-month period. Previous retrospective and prospective studies have reported the detection of adv in 5-30% of patients screened. 25 However, in this study, we were able to detect the presence of adv DNA in blood and/or stool in 81.8% of patients screened. This may be due to the high sensitivity of the Q-PCR assay or the frequency and duration over which samples were collected and screened. This high frequency of detection suggested there was a viral load which would indicate a greater likelihood of developing significant symptoms and risk of significant morbidity and mortality related to adv. When adv was detected in the blood and stool of MRD recipients, levels were generally low (blood: mean ¼ 667 cp/ml; stool: mean ¼ 1.2 Â 10 6 cp/ g). These patients were usually asymptomatic. This was in contrast to the MUD and Haplo patients where adv was detected at higher levels and earlier in the post-transplant period when the patients often displayed symptoms (MUD blood: mean ¼ 15 540 cp/ml, stool: mean ¼ 1.4 Â 10 9 cp/g; Haplo blood; mean ¼ 16 250 cp/ml, stool: mean ¼ 8.2 Â 10 7 cp/g). Finally, although we were able to detect adv by Q-PCR in the blood: of 37% (3/8) of our assymptomatic healthy control population, none of the controls had positive values of 41500 cp/ml (peak value ¼ 1100 cp/ml). Therefore, although adv can be detected even at very low levels using highly sensitive Q-PCR-based assays, this does not necessarily indicate significant infection. For these reasons, we designated 41500 cp/ml blood as our cutoff when defining viremia. Our incidence of adv disease (defined as the presence of viremia in symptomatic patients) was 36%, which is consistent with other published reports. 25 As we were able to detect adv by Q-PCR in the blood in 37% of our control population (albeit at levels o1500 cp/ ml), we investigated whether the source of adv in our patients was from the graft. We carried out Q-PCR analysis on stored aliquots of donor stem cell product and found no evidence of adv DNA. Although Runde et al. 9 had previously suggested that this was a possible source of infectious adv, it is unlikely that this was the causative effect in our patient cohort. We propose that most healthy individuals are intermittently asymptomatic carriers of adv as shown in our control group where asymptomatic personnel may be transiently positive for adv at low levels in the blood which in many cases corresponds to a rise in the adv-specific immune response ( Figure 5 ). Therefore, this further emphasizes the conclusion that infections developing early post-transplant are likely due to reactivation or de novo exposure to the virus in the peritransplant period.
Using a species-specific primer-probe combination, we were able to identify the species which was responsible for causing infections in our transplant recipients. In accordance with other reports, species C predominated in blood, whereas multiple species were present in the stool (Table 2) .
To better define the clinical relevance of Q-PCR positivity for adv we sought to correlate lymphocyte/T-cell recovery with the detection of viremia. We found no significant correlation between lymphocyte recovery and viremia in any of our patient groups and we observed that ALC and even CD4/8 count recovery are not necessarily reflective of the recovery of antigen-specific T cells. However, the recovery of adv-specific T cells was significantly faster in MRD recipients, where levels approached that of normal donors within 30 days post-HSCT, whereas this was significantly delayed in MUD and Haplo recipients (3-12 months) (Po0.05) who had all received in vivo T-cell depletion with alemtuzumab. Therefore, the clinical significance of detecting an elevated (>1500 cp/ml) adv Q-PCR result in recipients of alternative donor transplants is likely to be more meaningful than detecting adv in a patient 430 days post-MRD SCT where adv-specific immunity is rapidly restored. Furthermore, as MUD and Haplo recipients have a delayed recovery of adv-specific T cells, they are most likely to benefit from therapeutic intervention such as treatment with antiviral agents such as cidofovir or ribavirin. 16, 26, 27 However, these agents have associated toxicities and are not always effective. 7, 13, 28 A number of groups have demonstrated that adoptive immunotherapy with adv-specific T cells is another potential treatment option without related toxicity. [29] [30] [31] Interestingly, our group has seen resolution of infection through the withdrawal of immune suppression alone or withdrawal of immune suppression in combination with Tcell immunotherapy 32 without any toxicity. 10, 33 Recently, Feuchtinger et al. 12 showed that recovery of adv-specific T cells post-BMT was protective from lethal adv infection. They showed a significant difference in the number of adv-responsive, IFN-g secreting T cells in patients clearing adv infection and those with lethal adv infection or with no infection detected. Similarly, Heemskerk et al. 10 found humoral and cellular adv-specific immune responses to be delayed or detectable only after the clearance of adv viremia in many of their study patients. As our virus-specific immunotherapy protocols 33, 34 call for T-cell administration from day þ 30, we sought to better understand the timeline of recovery of adv-specific T-cells early post-transplant. Our study is unique because we have not only tried to define a Q-PCR value which has clinical relevance but also attempted to better define immune recovery to adv post-SCT in the context of transplant type and degree of immune suppression. In our study, recovery of adv-specific cellular immunity in MRD recipients was rapid, seemingly providing protection from viremia in a manner similar to what one might expect in an immune competent host. However, owing to the degree of T-cell depletion in the recipients of alternative donor transplants, the ability to mount an anti-adv T-cell response was delayed to at least 3 months (and up to 12 months) post-BMT.
In conclusion, we have sought to develop a strategy to help physicians in their dilemma of predicting patients who are at risk for symptomatic adv infection. We have defined viremia as 41500 adv cp/ml blood. However, a Q-PCR value alone is not predictive for symptomatic infection and requires interpretation with an assessment of the patient's cell-mediated immune response to adv. We demonstrated that ALC and absolute CD4/CD8 counts are not reliable tools to assess recovery of adv-specific immunity post-SCT. Therefore, in the absence of functional antigen-specific immune assays, clinicians should only consider initiating treatment strategies 15, 16, 32 after factoring in donor source, degree of T-cell depletion used, trend in adv load and timing post-transplant.
